They showed a 30% TTR in the Nf2 lesion alone and only 13% (6–28%) in Nf2flox/flox;p53± (heterozygous p53), however with a 91% rate of sarcomas/osteosarcomas over the course of a mere 165 days (median survival). The gene discussed is NF2; the disease is sarcoma.